Mustang Bio (MBIO) Competitors $1.57 +0.06 (+3.97%) Closing price 08/5/2025 04:00 PM EasternExtended Trading$1.50 -0.07 (-4.46%) As of 04:02 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock MBIO vs. DYAI, ESLA, RNTX, PMN, BDRX, ITRM, KZR, OKUR, IXHL, and GBIOShould you be buying Mustang Bio stock or one of its competitors? The main competitors of Mustang Bio include Dyadic International (DYAI), Estrella Immunopharma (ESLA), Rein Therapeutics (RNTX), Promis Neurosciences (PMN), Biodexa Pharmaceuticals (BDRX), Iterum Therapeutics (ITRM), Kezar Life Sciences (KZR), OnKure Therapeutics (OKUR), Incannex Healthcare (IXHL), and Generation Bio (GBIO). These companies are all part of the "pharmaceutical products" industry. Mustang Bio vs. Its Competitors Dyadic International Estrella Immunopharma Rein Therapeutics Promis Neurosciences Biodexa Pharmaceuticals Iterum Therapeutics Kezar Life Sciences OnKure Therapeutics Incannex Healthcare Generation Bio Dyadic International (NASDAQ:DYAI) and Mustang Bio (NASDAQ:MBIO) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their analyst recommendations, profitability, dividends, valuation, risk, earnings, media sentiment and institutional ownership. Which has more volatility and risk, DYAI or MBIO? Dyadic International has a beta of 0.89, suggesting that its share price is 11% less volatile than the S&P 500. Comparatively, Mustang Bio has a beta of 2.22, suggesting that its share price is 122% more volatile than the S&P 500. Which has preferable earnings & valuation, DYAI or MBIO? Dyadic International has higher revenue and earnings than Mustang Bio. Dyadic International is trading at a lower price-to-earnings ratio than Mustang Bio, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioDyadic International$3.49M8.45-$5.81M-$0.20-4.90Mustang BioN/AN/A-$15.75M-$78.00-0.02 Do insiders and institutionals believe in DYAI or MBIO? 28.0% of Dyadic International shares are held by institutional investors. Comparatively, 10.0% of Mustang Bio shares are held by institutional investors. 29.5% of Dyadic International shares are held by company insiders. Comparatively, 0.2% of Mustang Bio shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term. Does the media prefer DYAI or MBIO? In the previous week, Dyadic International had 5 more articles in the media than Mustang Bio. MarketBeat recorded 6 mentions for Dyadic International and 1 mentions for Mustang Bio. Dyadic International's average media sentiment score of 0.00 beat Mustang Bio's score of -1.00 indicating that Dyadic International is being referred to more favorably in the media. Company Overall Sentiment Dyadic International Neutral Mustang Bio Negative Is DYAI or MBIO more profitable? Mustang Bio has a net margin of 0.00% compared to Dyadic International's net margin of -163.94%. Mustang Bio's return on equity of 0.00% beat Dyadic International's return on equity.Company Net Margins Return on Equity Return on Assets Dyadic International-163.94% -233.69% -59.37% Mustang Bio N/A N/A -80.79% Do analysts rate DYAI or MBIO? Dyadic International presently has a consensus target price of $6.00, indicating a potential upside of 512.12%. Given Dyadic International's stronger consensus rating and higher probable upside, analysts plainly believe Dyadic International is more favorable than Mustang Bio.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Dyadic International 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00Mustang Bio 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 SummaryDyadic International beats Mustang Bio on 11 of the 15 factors compared between the two stocks. Get Mustang Bio News Delivered to You Automatically Sign up to receive the latest news and ratings for MBIO and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding MBIO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart MBIO vs. The Competition Export to ExcelMetricMustang BioMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$6.61M$3.07B$5.59B$9.53BDividend YieldN/A2.41%4.73%4.14%P/E Ratio-0.0217.5328.9123.88Price / SalesN/A313.17448.7998.82Price / CashN/A42.6035.6858.35Price / Book-0.747.828.165.60Net Income-$15.75M-$54.52M$3.25B$265.26M7 Day Performance2.61%2.86%1.15%-0.14%1 Month Performance29.22%17.29%8.25%6.08%1 Year Performance-90.53%13.27%29.18%24.22% Mustang Bio Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)MBIOMustang Bio0.1929 of 5 stars$1.57+4.0%N/A-88.5%$6.61MN/A-0.02100Negative NewsUpcoming EarningsDYAIDyadic International2.5744 of 5 stars$1.11+0.9%$6.00+440.5%-26.3%$33.10M$3.49M-5.557News CoverageUpcoming EarningsESLAEstrella Immunopharma2.3782 of 5 stars$0.92+1.1%$16.00+1,639.1%-40.5%$32.91MN/A-3.54N/ARNTXRein TherapeuticsN/A$1.41-3.4%N/AN/A$32.34MN/A-0.499Positive NewsPMNPromis Neurosciences2.0375 of 5 stars$0.90-8.8%$4.33+381.4%-44.2%$32.25MN/A-18.005BDRXBiodexa Pharmaceuticals0.0799 of 5 stars$0.88flatN/AN/A$32.16M$470K0.0020News CoverageShort Interest ↑ITRMIterum Therapeutics1.6057 of 5 stars$0.78-2.8%$9.00+1,053.8%-39.0%$32.10MN/A-0.7910News CoverageShort Interest ↑KZRKezar Life Sciences3.5068 of 5 stars$4.36+1.2%$39.50+806.0%-30.4%$31.49M$7M-0.4060Positive NewsUpcoming EarningsShort Interest ↑OKUROnKure Therapeutics2.8391 of 5 stars$2.28-1.3%$32.33+1,318.1%N/A$31.21MN/A-0.43N/AUpcoming EarningsIXHLIncannex Healthcare0.2609 of 5 stars$1.19+13.3%N/A-80.1%$30.91M$10K-0.983Gap DownGBIOGeneration Bio3.7148 of 5 stars$4.70+2.0%$80.00+1,602.1%-80.0%$30.90M$19.89M-0.44150 Related Companies and Tools Related Companies DYAI Alternatives ESLA Alternatives RNTX Alternatives PMN Alternatives BDRX Alternatives ITRM Alternatives KZR Alternatives OKUR Alternatives IXHL Alternatives GBIO Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:MBIO) was last updated on 8/6/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredGENIUS Act: Cancel Your Money?They said digital dollars were off the table. But with the GENIUS Act now federal law, private corporations—no...Priority Gold | Sponsored[Shocking New Report] U.S. Dollar To Crash?The "Death Spiral" Threatening Your Savings But this time, it's not just Dalio ringing the alarm bells…Goldco Precious Metals | SponsoredCrypto bros: Meet your replacementLarry Benedict made $274 million trading on Wall Street… Barron’s ranked his hedge fund in the top 1% world...Brownstone Research | Sponsored[Warning] Buffett Indicator hits new All-Time-HighWarren Buffett has leaned on one key indicator for decades—and it just hit an all-time high. That’s not bullis...Golden Portfolio | SponsoredThe Robotics Revolution has arrived … and one $7 stock could take off as a result.Something big is brewing in Washington. According to my research, an executive order from President Trump c...Weiss Ratings | SponsoredMarket Crash Warning: How to Protect Your Wealth Before August 12thChina tariffs hit August 12—and experts warn a market meltdown may follow. A free guide from American Alter...American Alternative | SponsoredWhy AMZN, GOOG, MSFT might destroy NVDAInvesting Legend Hints the End May be Near for These 3 Iconic Stocks Futurist Eric Fry say Amazon, Tesla an...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Mustang Bio, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Mustang Bio With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free MBIO Stock Alerts